Interferon-Independent Upregulation of Interferon-Stimulated Genes during Human Cytomegalovirus Infection is Dependent on IRF3 Expression.


Journal

Viruses
ISSN: 1999-4915
Titre abrégé: Viruses
Pays: Switzerland
ID NLM: 101509722

Informations de publication

Date de publication:
12 03 2019
Historique:
received: 31 01 2019
revised: 25 02 2019
accepted: 07 03 2019
entrez: 16 3 2019
pubmed: 16 3 2019
medline: 19 9 2019
Statut: epublish

Résumé

The antiviral activity of type I interferons (IFNs) is primarily mediated by interferon-stimulated genes (ISGs). Induction of ISG transcription is achieved when type I IFNs bind to their cognate receptor and activate the Janus Kinase/Signal Transducer and Activator of Transcription (JAK/STAT) signaling pathways. Recently it has become clear that a number of viruses are capable of directly upregulating a subset of ISGs in the absence of type I IFN production. Using cells engineered to block either the response to, or production of type I IFN, the regulation of IFN-independent ISGs was examined in the context of human cytomegalovirus (HCMV) infection. Several ISGs, including IFIT1, IFIT2, IFIT3, Mx1, Mx2, CXCL10 and ISG15 were found to be upregulated transcriptionally following HCMV infection independently of type I IFN-initiated JAK-STAT signaling, but dependent on intact IRF3 signaling. ISG15 protein regulation mirrored that of its transcript with IFNβ neutralization failing to completely inhibit ISG15 expression post HCMV infection. In addition, no detectable ISG15 protein expression was observed following HCMV infection in IRF3 knockdown CRISPR/Cas-9 clones indicating that IFN-independent control of ISG expression during HCMV infection of human fibroblasts is absolutely dependent on IRF3 expression.

Identifiants

pubmed: 30871003
pii: v11030246
doi: 10.3390/v11030246
pmc: PMC6466086
pii:
doi:

Substances chimiques

Cytokines 0
IRF3 protein, human 0
Interferon Regulatory Factor-3 0
Ubiquitins 0
ISG15 protein, human 60267-61-0
Interferon-beta 77238-31-4
Interferons 9008-11-1

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Références

J Virol. 2001 Oct;75(19):8909-16
pubmed: 11533154
Clin Vaccine Immunol. 2006 Nov;13(11):1181-4
pubmed: 16957061
Virology. 2000 Feb 15;267(2):209-19
pubmed: 10662616
Rev Med Virol. 2010 Jul;20(4):202-13
pubmed: 20564615
Rev Med Virol. 2014 Sep;24(5):291-307
pubmed: 24760655
PLoS Pathog. 2013;9(8):e1003497
pubmed: 23935494
EMBO J. 1998 Nov 16;17(22):6660-9
pubmed: 9822609
J Virol. 2003 Apr;77(8):4588-96
pubmed: 12663765
PLoS One. 2018 Jul 25;13(7):e0200267
pubmed: 30044826
J Gen Virol. 2017 Jul;98(7):1795-1805
pubmed: 28745271
J Virol. 2018 Jul 17;92(15):
pubmed: 29743376
PLoS Pathog. 2012 Jan;8(1):e1002498
pubmed: 22291595
Nature. 2011 Apr 28;472(7344):481-5
pubmed: 21478870
J Virol. 2006 Jan;80(2):1032-7
pubmed: 16379004
J Mol Biol. 2014 Mar 20;426(6):1210-9
pubmed: 24157441
EMBO J. 1998 Feb 16;17(4):1087-95
pubmed: 9463386
PLoS Pathog. 2015 Dec 08;11(12):e1005324
pubmed: 26646986
J Virol. 2002 Mar;76(5):2159-67
pubmed: 11836393
J Virol. 2004 Feb;78(4):1706-17
pubmed: 14747536
J Gen Virol. 2000 Sep;81(Pt 9):2215-2218
pubmed: 10950979
J Virol. 2008 May;82(9):4585-94
pubmed: 18287244
PLoS Pathog. 2016 Aug 26;12(8):e1005850
pubmed: 27564865
Cell Host Microbe. 2011 Dec 15;10(6):534-9
pubmed: 22177558
Med J Aust. 2011 Jun 20;194(12):625-9
pubmed: 21692718
Cell. 1992 Jul 24;70(2):323-35
pubmed: 1638633
J Virol. 2001 Dec;75(24):12319-30
pubmed: 11711622
Science. 2015 Mar 13;347(6227):aaa2630
pubmed: 25636800
J Pak Med Assoc. 2016 Aug;66(8):1009-14
pubmed: 27524538
J Virol. 2015 Jan 15;89(2):1479-83
pubmed: 25392213
Nucleic Acids Res. 2013 Jan;41(Database issue):D1040-6
pubmed: 23203888
J Clin Invest. 2010 Sep;120(9):3191-208
pubmed: 20679731
Clin Infect Dis. 2006 Nov 1;43(9):1143-51
pubmed: 17029132
J Pathol. 2015 Jan;235(2):288-97
pubmed: 25205255
J Clin Virol. 2009 Dec;46 Suppl 4:S6-10
pubmed: 19800841
J Virol. 2010 Jan;84(1):585-98
pubmed: 19846511
Prev Med. 2012 May;54(5):351-7
pubmed: 22465669
Proc Natl Acad Sci U S A. 1997 Dec 9;94(25):13985-90
pubmed: 9391139
Eur J Biochem. 1992 Jun 15;206(3):901-10
pubmed: 1318841
J Virol. 2006 Dec;80(23):11723-32
pubmed: 16971436
J Med Virol. 1988 Dec;26(4):363-73
pubmed: 2850341
Prenat Diagn. 2010 Sep;30(9):888-92
pubmed: 20715119
J Virol. 2002 Jun;76(11):5532-9
pubmed: 11991981
Curr Top Microbiol Immunol. 2008;325:187-204
pubmed: 18637507
J Virol. 2004 Feb;78(3):1202-11
pubmed: 14722275
Nat Methods. 2014 Aug;11(8):783-784
pubmed: 25075903
Proc Natl Acad Sci U S A. 1995 Dec 5;92(25):11657-61
pubmed: 8524823
Science. 2013 Feb 15;339(6121):786-91
pubmed: 23258413
J Leukoc Biol. 1994 Mar;55(3):299-309
pubmed: 7509841
Clin Microbiol Rev. 2009 Jan;22(1):99-126, Table of Contents
pubmed: 19136436
J Virol. 2014 Sep;88(18):10990-4
pubmed: 25008927
J Virol. 2018 Nov 27;92(24):
pubmed: 30282718
J Immunol. 2010 May 1;184(9):5179-85
pubmed: 20308629
J Virol. 2017 Apr 13;91(9):
pubmed: 28202760
J Immunol. 2006 Nov 15;177(10):7094-102
pubmed: 17082626
Virol J. 2005 Feb 23;2:14
pubmed: 15727684
Proc Natl Acad Sci U S A. 2001 Dec 18;98(26):15125-30
pubmed: 11752458
Microbiol Immunol. 1999;43(12):1087-96
pubmed: 10656176
J Virol. 1997 Jul;71(7):5051-9
pubmed: 9188570

Auteurs

Caroline L Ashley (CL)

Department of Infectious Diseases and Immunology, Charles Perkins Centre, University of Sydney, Camperdown, New South Wales 2050, Australia. cash7683@uni.sydney.edu.au.

Allison Abendroth (A)

Department of Infectious Diseases and Immunology, Charles Perkins Centre, University of Sydney, Camperdown, New South Wales 2050, Australia. allison.abendroth@sydney.edu.au.

Brian P McSharry (BP)

Department of Infectious Diseases and Immunology, Charles Perkins Centre, University of Sydney, Camperdown, New South Wales 2050, Australia. brian.mcsharry@sydney.edu.au.

Barry Slobedman (B)

Department of Infectious Diseases and Immunology, Charles Perkins Centre, University of Sydney, Camperdown, New South Wales 2050, Australia. barry.slobedman@sydney.edu.au.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH